Ranked one of the best clinical decision support tools for health professionals worldwide, BMJ Best Practice provides step-by-step guidance on diagnosis, treatment and prevention.
Updated daily using robust evidence-based methodology and expert opinion, BMJ Best Practice provides you with access to the very latest clinical information.
WHO recommends fexinidazole for rhodesiense HAT
The World Health Organization (WHO) has updated its guidelines for the management of human African trypanosomiasis (HAT). HAT is a serious, life-threatening disease, with approximately 55 million people at risk of infection in 36 sub-Saharan countries.
Clinicians urged to consider parvovirus B19 in people with fever, myalgia, arthralgia, and rash, after US and Europe report increased cases
Recent data indicates an increase in parvovirus B19 activity, the virus responsible for erythema infectiosum. Since March 2024, there has been a significant rise in cases reported in 14 European countries, and in August 2024, the US Centers for Disease Control and Prevention (CDC) issued a Health Alert about increased activity in the US.
FDA approves palopegteriparatide for hypoparathyroidism in adults
The US Food and Drug Administration (FDA) has approved palopegteriparatide for the treatment of hypoparathyroidism in adults. It is the first and only treatment approved for hypoparathyroidism.
WHO declares mpox outbreak in Africa a public health emergency of international concern; first cases of clade Ib mpox detected in UK
The World Health Organization (WHO) declared the current mpox outbreak in Africa a public health emergency of international concern (PHEIC) on the 14th August 2024. PHEIC status aims to accelerate funding, research, and international public health measures and co-operation to contain a disease, and is the WHO’s highest level of alert possible.
The highest ranking* CDS app
Access clinical information anywhere, even offline, with our award-winning app.
Whether you’re on the ward, at home, or studying, the BMJ Best Practice app gives you trusted decision support information in an instant. The app is provided for free to those who have a personal subscription to BMJ Best Practice or have access provided by their institution.
* As of 23 August 2023
It’s no understatement to say that this app (and the website) is responsible for getting me through medical school. Nowhere else can you get such succinct and relevant summaries and treatment algorithms.
BMJ Best Practice app user
Introducing our new Frailty topic
Unlock essential insights into frailty with the latest addition to BMJ Best Practice
Recognising frailty is crucial. It’s an independent risk factor for adverse health outcomes, such as increased hospitalisations. By identifying frailty, we can tailor interventions to mitigate risks and improve outcomes. This topic is designed to equip you with the tools you need to navigate the complexities of frailty management, by helping you to:
- Identify frailty
- Navigate an ageing population
- Understand the implications of frailty
- Support the MDT
Have you used our Comorbidities Manager?
Managing the treatment of patients with comorbidities is hard – clinical guidelines only focus on single conditions – but failure to manage comorbidities leads to worse clinical outcomes and longer lengths of stay.
Our unique Comorbidities Manager* provides guidance on the treatment of a patient’s acute condition alongside their preexisting comorbidities.
*This feature is only available if your institution has purchased the Comorbidities Manager. If you have access it will appear under the ‘Your Profile’ section in the menu at the top of the page.
At a glance
One in three adults suffer from multiple chronic conditions and most patients in the acute setting have more than one medical condition.
- Treat patients with comorbidities with confidence
- Better understand the complexities of treating multiple conditions
- Achieve better outcomes for patients